Smoking Ups Long-Term Risks From Radiotherapy in Breast CA

This article originally appeared here.
Share this content:
Smoking Ups Long-Term Risks From Radiotherapy in Breast CA
Smoking Ups Long-Term Risks From Radiotherapy in Breast CA

MONDAY, March 27, 2017 (HealthDay News) -- For patients with breast cancer, the absolute risks associated with modern radiotherapy are higher for smokers than nonsmokers, according to research published online March 20 in the Journal of Clinical Oncology.

Carolyn Taylor, D.Phil., from the University of Oxford in the United Kingdom, and colleagues estimated the absolute long-term risks of modern breast cancer radiotherapy. They conducted a systematic literature review of lung and heart doses in breast cancer regimens published from 2010 to 2015. Individual patient data for 40,781 women randomized to breast cancer radiotherapy versus no radiotherapy were meta-analyzed to yield rate ratios (RRs) for second primary cancers and cause-specific mortality and excess rate ratios (ERRs) for incident lung cancer and cardiac mortality per Gy.

The researchers found that the average radiation doses were 5.7 and 4.4 Gy for whole lung and whole heart, respectively. Lung cancer incidence ≥10 years after radiotherapy had a RR of 2.10 on the basis of 134 cancers (0.11 ERR per Gy whole-lung dose). On the basis of 1,253 cardiac deaths, the RR was 1.30 for cardiac mortality (0.04 ERR per Gy whole-heart dose). The estimated absolute risks from modern radiotherapy were about 4 and 0.3 percent for long-term continuing smokers and nonsmokers, respectively, for lung cancer, and 1 and 0.3 percent for smokers and nonsmokers, respectively, for cardiac mortality.

"Smoking can determine the net effect of radiotherapy on mortality, but smoking cessation substantially reduces radiotherapy risk," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text
Editorial

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »